Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0WXQJL)
| ADC Name |
Vadastuximab talirine
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
vadastuximab talirine; SGN-CD33A
Click to Show/Hide
|
|||||
| Organization |
Seagen (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 3 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Vadastuximab
|
Antibody Info | ||||
| Antigen Name |
Myeloid cell surface antigen CD33 (CD33)
|
Antigen Info | ||||
| Payload Name |
SGD-1882
|
Payload Info | ||||
| Payload Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
| Combination Type |
talirine
|
|||||
| Special Approval(s) |
Orphan drug (FDA)
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility required untreated MDS (WHO 2008) patients ≥18 years with ECOG ≤2 and adequate organ function, excluding prior lenalidomide/HMA treatment, active secondary malignancies (except hormonal therapies), or candidates for immediate stem cell transplant.
|
||||
| Administration Dosage |
Intravenous (IV) push every 4 weeks
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02706899 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS) | ||||
| Primary Endpoint |
The phase 1 study evaluating vadastuximab talirine was terminated before establishing a recommended phase 2 dose, with only dose delays/reductions reported, while phase 2 efficacy endpoints (ORR, CR, HI, DOR, PFS, AML transformation, OS) were not assessed due to study discontinuation.
|
||||
| Other Endpoint |
Safety analysis captured adverse events and lab abnormalities over 1 year, though all planned phase 2 efficacy comparisons per IWG 2006 criteria (including CR rate, hematologic improvement, and survival outcomes) remained unevaluated following early trial termination.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible patients had untreated intermediate/adverse-risk AML (WHO-classified, excluding APL/favorable karyotypes) suitable for HMA therapy, while excluding prior MDS treatment recipients, transplant candidates, and those with myeloproliferative neoplasm histories.
|
||||
| Administration Dosage |
33A, 10 mcg/kg, every 4 weeks via intravenous (IV) push
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02785900 | Clinical Status | PHASE3 | ||
| Clinical Description | A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | ||||
| Primary Endpoint |
The study evaluated overall survival (1.5 years) and composite complete remission (CRc) rate per Cheson 2003 criteria, while assessing MRD-negative CRc status and time to CR/CRi within the same timeframe.
|
||||
| Other Endpoint |
Secondary endpoints included duration of remission (9.5 months), event-free survival (11.24 months), leukemia-free survival (9.49 months), safety profile (TEAEs, grade ≥3 lab abnormalities over 1.5 years), and 30-/60-day mortality rates, with censoring rules applied for patients receiving subsequent therapies.
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Eligible participants had CD33+ AML with ECOG 0-1, adequate organ function, and either relapsed after ≥12-week remission or were untreated with ≥20% blasts, excluding recent transplant recipients (except designated cohort) or those receiving recent antileukemic therapy.
|
||||
| Administration Dosage |
Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01902329 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia | ||||
| Primary Endpoint |
The study monitored adverse events and laboratory abnormalities through 1 month post-treatment, while evaluating pharmacokinetics (SGN-CD33A blood concentrations for 3 weeks) and immunogenicity (antitherapeutic antibody incidence).
|
||||
| Other Endpoint |
Efficacy assessments included complete remission rate (3 months), duration of response (3 years), relapse-free survival (3 years), and overall survival (3 years) in CD33-positive AML patients.
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Patients Enrolled |
The trial enrolled AML patients (excluding APL) with ECOG 0-1 and adequate organ function, stratifying by treatment phase (induction/consolidation/maintenance), while excluding those with prior MDS/MPN therapy or cardiopulmonary dysfunction in dose-escalation cohorts.
|
||||
| Administration Dosage |
7+3 (Standard dose cytarabine for induction and daunorubicin) + SGN-CD33A Drug: SGN-CD33A, Given intravenously Day 1 or Days 1 and 4 of each cycle
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02326584 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia | ||||
| Primary Endpoint |
Safety assessments included adverse events, laboratory abnormalities, and dose-limiting toxicities monitored through 1 month post-treatment, establishing the preliminary safety profile of SGN-CD33A in AML patients.
|
||||
| Other Endpoint |
Efficacy outcomes measured CR rate post-induction, leukemia-free survival, and overall survival (up to 3 years), while pharmacokinetic parameters (drug concentrations, ATA incidence) and MRD clearance rates were tracked longitudinally throughout the study duration.
|
||||
| Experiment 5 Reporting the Activity Date of This ADC | [5] | ||||
| Patients Enrolled |
Inclusion criteria: Adults ≥18 with isolated distal femur fractures requiring LISS plating, compliant with 1-year MGH follow-ups. Exclusion: Life expectancy <1 year, pre-injury non-ambulatory status, pregnancy, non-LISS implants, bone disorders, neoplasm-related fractures, severe open fractures with vascular damage, or inability to attend follow-ups.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01593176 | Clinical Status | N.A. | ||
| Clinical Description | Radiostereometric Analysis of Fracture Healing in Distal Femur Fractures | ||||
| Primary Endpoint |
The study evaluates inter-fragmentary motion changes in distal femoral fractures using radiostereometric analysis at postoperative intervals (2 weeks, 6 weeks, 3/6/12 months) to assess healing dynamics.
|
||||
| Experiment 6 Reporting the Activity Date of This ADC | [6] | ||||
| Efficacy Data | Incomplete Count Recovery (CRi) |
26%
|
|||
| Patients Enrolled |
Older patients with newly diagnosed acute myeloid leukemia (AML).
|
||||
| Administration Dosage |
33A, iv, 10 mcg/kg, every 4 weeks plus azacitidine 75 mg/m2, SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m2, iv x 5 days, every 4 weeks; placebo plus plus azacitidine 75 mg/m2, SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m2, iv x 5 days, every 4 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02326584 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia. | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Complete Remission (CR) |
66.70%
|
|||
| Patients Enrolled |
Patients With Relapsed or Refractory AmL.
|
||||
| Administration Dosage |
Post-allo after stem cell transplant in Day 1 of each cycle; Pre-allo in Day 1 of each cycle plus melphalan 30 mg/m2/day iv and fludarabine 140 mg/m2 iv before stem cell transplant.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02785900 | Clinical Status | Phase 3 | ||
| Clinical Description | A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML). | ||||
| Experiment 8 Reporting the Activity Date of This ADC | [8] | ||||
| Efficacy Data | Complete Remission (CR) |
11.00
12.00 22.00 23.00 % |
|||
| Patients Enrolled |
CD33-positive AmL (any level of CD33 expression as detected by local flow cytometric assessment) and had either newly diagnosed AmL (declining intensive induction/consolidation chemotherapy) or AmL relapsed after a minimum remission duration of 12 weeks after intensive induction/consolidation.
|
||||
| Administration Dosage |
Slow IV push on day 1 (5-60 ug/kg) or on days 1 and 4 (20 ug/kg) of 21-day cycles.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01902329 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia. | ||||
| Primary Endpoint |
The recommended monotherapy dose is 4.00 mg/kg.
|
||||
| Other Endpoint |
The complete remission rate (CRc) among the 69 patients in the dose-finding cohorts, was 19.00% (6.00% CR + 13.00% CRi, 95% confidence interval [CI], 10.40-30.10).
|
||||
| Experiment 9 Reporting the Activity Date of This ADC | [6] | ||||
| Efficacy Data | Complete Remission (CR) |
30.00
26.00 % |
|||
| Patients Enrolled |
Older patients with newly diagnosed acute myeloid leukemia (AML).
|
||||
| Administration Dosage |
33A, iv, 10 mcg/kg, every 4 weeks plus azacitidine 75 mg/m2, SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m2, iv x 5 days, every 4 weeks; placebo plus plus azacitidine 75 mg/m2, SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m2, iv x 5 days, every 4 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02326584 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia. | ||||
| Experiment 10 Reporting the Activity Date of This ADC | [9] | ||||
| Efficacy Data | Complete Remission (CR) |
43.00
42.00 34.00 80.00 50.00 39.00 % |
|||
| Patients Enrolled |
New diagnosis of CD33-expressing AmL, they could not have received prior therapy with HMAs; however, prior low-intensity treatment, such as hydroxyurea for cytoreduction or other low-intensity therapies for preceding myelodysplastic syndrome (MDS), an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, with adequate baseline renal, hepatic, and pulmonary function.
Click to Show/Hide
|
||||
| Administration Dosage |
Azacitidine (75 mg/m2 subcutaneous/intravenous 7 days) or decitabine (20 mg/m2 intravenous 5 days) was administered per institutional standard. On the final day of HMA administration (day 7 of azacitidine treatment and day 5 of decitabine treatment), vadastuximab talirine (10 ug/kg) was administered via slow intravenous push (1-2 mL/min), after infusion of the HMA, as 28-day cycles for up to 4 cycles of treatment.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01902329 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia. | ||||
| Primary Endpoint |
The 30- and 60-day mortality rates were 2% and 8%, respectively. No DLTs or infusion-related reactions were observed in the combination cohort of this study.
|
||||
| Other Endpoint |
CR and CRi, was 70.00% (43% CR + 26% CRi, 95% CI, 55.70-81.70). Median RFS was 7.70 months (95% CI, 4.90-15.40) with 11.30 months (95% CI, 8.80-13.20) median OS.
|
||||
| Experiment 11 Reporting the Activity Date of This ADC | [10] | ||||
| Patients Enrolled |
Patients with operable HER2-positive primary breast cancer.
|
||||
| Administration Dosage |
Anthracycline then Trastuzumab Emtansine and Pertuzumab ; Anthracycline then Trastuzumab, Pertuzumab, and Taxane.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02614560 | Clinical Status | Phase 1/2 | ||
| Clinical Description | A phase 1/2 study of vadastuximab talirine administered in sequence with allogeneic hematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukemia (AML). | ||||
| Experiment 12 Reporting the Activity Date of This ADC | [11] | ||||
| Patients Enrolled |
Patients With acute myeloid leukemia (AML).
|
||||
| Administration Dosage |
SGN-CD33A iv in Day 1 or Days 1 and 4 of each cycle; High dose cytarabine + SGN-CD33A (28-day cycles); Standard dose cytarabine and daunorubicin + SGN-CD33A; standard dose cytarabine and daunorubicin + SGN-CD33A and High dose cytarabine + SGN-CD33A.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01902329 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia. | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0% | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 100mcg/kg.
|
||||
| In Vitro Model | Erythroleukemia | HEL 92.1.7 cells (Multidrug resistance) | CVCL_2481 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 29.44% | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 30mcg/kg.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 47.77% | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 300mcg/kg.
|
||||
| In Vitro Model | Erythroleukemia | HEL 92.1.7 cells (Multidrug resistance) | CVCL_2481 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 78.95% | Negative CD33 expression (CD33-) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 100mcg/kg.
|
||||
| In Vitro Model | Anaplastic thyroid cancer | TF1-alpha cells (Multidrug resistance) | Homo sapiens | ||
| Experiment 5 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.41% | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 1000mcg/kg.
|
||||
| In Vitro Model | Erythroleukemia | HEL 92.1.7 cells (Multidrug resistance) | CVCL_2481 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.53% | Negative CD33 expression (CD33-) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 300mcg/kg.
|
||||
| In Vitro Model | Anaplastic thyroid cancer | TF1-alpha cells (Multidrug resistance) | Homo sapiens | ||
| Experiment 7 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.99% | Negative CD33 expression (CD33-) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 300mcg/kg.
|
||||
| In Vitro Model | Anaplastic thyroid cancer | TF1-alpha cells (Multidrug resistance) | Homo sapiens | ||
| Experiment 8 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.99% | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 100mcg/kg.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.1 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=3,919) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG019 | Homo sapiens | ||
| Experiment 2 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.1 ng/mL | Moderate CD33 expression (CD33++; 6,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.2 ng/mL | High CD33 expression (CD33+++; CD33 MFI=11,850) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG015 | Homo sapiens | ||
| Experiment 4 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.2 ng/mL | High CD33 expression (CD33+++; CD33 MFI=10,762) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG018 | Homo sapiens | ||
| Experiment 5 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.2 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG023 | Homo sapiens | ||
| Experiment 6 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.2 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=1,355) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG014 | Homo sapiens | ||
| Experiment 7 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.2 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG022 | Homo sapiens | ||
| Experiment 8 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.4 ng/mL | Low CD33 expression (CD33+; CD33 MFI=107) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG003 | Homo sapiens | ||
| Experiment 9 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.9 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=5,817) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG002 | Homo sapiens | ||
| Experiment 10 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | KG-1 cells | CVCL_0374 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5 ng/mL | Negative CD33 expression (CD33-; CD33 MFI=20) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG017 | Homo sapiens | ||
| Experiment 13 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 6 ng/mL | Negative CD33 expression (CD33-; CD33 MFI=49) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG001 | Homo sapiens | ||
| Experiment 14 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 6 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | SH-1 cells | CVCL_2191 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 7 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | THP-1 cells | CVCL_0006 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 7 ng/mL | High CD33 expression (CD33+++; CD33 MFI=23,223) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Erythroleukemia | HEL 92.1.7 cells | CVCL_2481 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 7.5 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | SIG-M5 cells | CVCL_1694 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 11 ng/mL | Low CD33 expression (CD33+; CD33 MFI=216) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG013 | Homo sapiens | ||
| Experiment 19 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 11 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=1,035) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG008 | Homo sapiens | ||
| Experiment 20 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 22 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Adult acute monocytic leukemia | U-937 cells | CVCL_0007 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 23 ng/mL | Low CD33 expression (CD33+; CD33 MFI=299) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG010 | Homo sapiens | ||
| Experiment 22 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 26 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | HNT-34 cells | CVCL_2071 | ||
| Experiment 23 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 32 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=1,184) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG004 | Homo sapiens | ||
| Experiment 24 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 33 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=6,598) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG011 | Homo sapiens | ||
| Experiment 25 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 49 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=2,278) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Anaplastic thyroid cancer | TF1-alpha cells (Multidrug resistance) | Homo sapiens | ||
| Experiment 26 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 61 ng/mL | Moderate CD33 expression (CD33++; 7,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Esophageal squamous cell carcinoma | TF-1 cells | CVCL_1759 | ||
| Experiment 27 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 68 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | SH-2 cells | CVCL_2190 | ||
| Experiment 28 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 100 ng/mL | Negative CD33 expression (CD33-; CD33 MFI=0) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG009 | Homo sapiens | ||
| Experiment 29 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 110 ng/mL | Low CD33 expression (CD33+; CD33 MFI=353) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG012 | Homo sapiens | ||
| Experiment 30 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 110 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG020 | Homo sapiens | ||
| Experiment 31 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 1000 ng/mL | Low CD33 expression (CD33+; CD33 MFI=318) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Ovarian clear cell adenocarcinoma | ES-2 cells | CVCL_3509 | ||
| Experiment 32 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 1000 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 33 Reporting the Activity Date of This ADC | [12] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 5000 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
References